Cowen

Littelfuse to Participate in Virtual Investor Conferences

Retrieved on: 
Tuesday, May 25, 2021

Littelfuse, Inc. (NASDAQ: LFUS), an industrial technology manufacturing company empowering a sustainable, connected, and safer world, announced today it will participate in the following virtual investor conferences:

Key Points: 
  • Littelfuse, Inc. (NASDAQ: LFUS), an industrial technology manufacturing company empowering a sustainable, connected, and safer world, announced today it will participate in the following virtual investor conferences:
    June 2 - Cowen Technology, Media & Telecom Conference
    June 10 - Baird Global Consumer, Technology & Services Conference
    Contact your Cowen, Stifel or Baird representative to schedule a call with management.
  • Interested parties can access a live webcast of the Cowen and Stifel presentations on the investor relations page of the companys website, Littelfuse.com .
  • Littelfuse (NASDAQ: LFUS) is an industrial technology manufacturing company empowering a sustainable, connected, and safer world.
  • Across more than 15 countries, and with 12,000 global associates, we partner with customers to design and deliver innovative, reliable solutions.

Cowen and PolySign to Launch Strategic Partnership Geared Toward Providing Clients Access to Cryptocurrency and Digital Assets

Retrieved on: 
Thursday, May 13, 2021

In support of the partnership, Cowen has made a $25 million strategic investment in PolySign, leading the $53 million initial closing of PolySign\xe2\x80\x99s Series B financing.

Key Points: 
  • In support of the partnership, Cowen has made a $25 million strategic investment in PolySign, leading the $53 million initial closing of PolySign\xe2\x80\x99s Series B financing.
  • \xe2\x80\x9cCowen\xe2\x80\x99s partnership and investment in PolySign validates the strength of our technology and team, as well as the growing significance of digital assets as an asset class.
  • Institutional-grade, regulated custody solutions for a wide array of digital assets will be provided by Standard Custody & Trust Company (\xe2\x80\x9cStandard\xe2\x80\x9d), a PolySign subsidiary.
  • Other terms of the investment or partnership were not disclosed.\nCowen and Company, LLC and SenaHill acted as financial advisors to Cowen.

Brian Holland Joins Cowen’s Equity Research Team as Senior Analyst for Sustainable Food & Healthy Living

Retrieved on: 
Tuesday, April 27, 2021

b'NEW YORK, April 27, 2021 (GLOBE NEWSWIRE) -- Cowen Inc. (NASDAQ:COWN) (\xe2\x80\x9cCowen\xe2\x80\x9d or the \xe2\x80\x9cCompany\xe2\x80\x9d) today announced that Brian Holland has joined the Company\xe2\x80\x99s equity research team to cover sustainable food & healthy living, a new sector vertical at Cowen anchored in food innovation, sustainable agriculture technology and other emerging products and business models focused on health and wellness.

Key Points: 
  • b'NEW YORK, April 27, 2021 (GLOBE NEWSWIRE) -- Cowen Inc. (NASDAQ:COWN) (\xe2\x80\x9cCowen\xe2\x80\x9d or the \xe2\x80\x9cCompany\xe2\x80\x9d) today announced that Brian Holland has joined the Company\xe2\x80\x99s equity research team to cover sustainable food & healthy living, a new sector vertical at Cowen anchored in food innovation, sustainable agriculture technology and other emerging products and business models focused on health and wellness.
  • He also held positions at Consumer Edge Research and Janney Capital Markets.
  • Cowen focuses on delivering value-added capabilities to our clients in order to help them outperform.
  • Founded in 1918, the Company is headquartered in\xc2\xa0New York\xc2\xa0and has offices worldwide.

MKM Partners Hires Senior Travel Analyst as the Firm Continues to Expand Its Research Department at New Corporate Headquarters

Retrieved on: 
Tuesday, April 27, 2021

b'STAMFORD, Conn., April 27, 2021 /PRNewswire/ -- MKM Partners is pleased to announce the addition of Conor Cunningham to its award-winning research department as Executive Director, Senior Travel Analyst.

Key Points: 
  • b'STAMFORD, Conn., April 27, 2021 /PRNewswire/ -- MKM Partners is pleased to announce the addition of Conor Cunningham to its award-winning research department as Executive Director, Senior Travel Analyst.
  • Conor has nearly fifteen years of experience in both research and financial services, most recently at Cowen and Companycovering Airlines, Transportation and Leasing.
  • Prior to Cowen, Conor worked as an Equity Research Associate at Dahlman Rose & Co.and Jesup & Lamont.
  • MKM combines high-impact fundamental analysis with macroeconomics, technical insights, derivatives strategies, event-driven commentary, alternative research, and first-rate execution.

CM Life Sciences III Inc., Sponsored by Affiliates of Casdin Capital and Corvex Management, Announces Closing of $552 Million Initial Public Offering

Retrieved on: 
Friday, April 9, 2021

The units are listed on The Nasdaq Capital Market (Nasdaq) and began trading under the ticker symbol CMLTU on April 7, 2021.

Key Points: 
  • The units are listed on The Nasdaq Capital Market (Nasdaq) and began trading under the ticker symbol CMLTU on April 7, 2021.
  • The Company, sponsored by affiliates of Casdin Capital, LLC and Corvex Management LP, is led by Chief Executive Officer Eli Casdin and Chairman Keith Meister.
  • The Company intends to focus its search for business combination targets in three separate areas of the life sciences industry that are often fragmented life sciences tools, synthetic biology and diagnostics.
  • Jefferies LLC and Cowen and Company, LLC served as the joint book runners for the offering.

Panacea Acquisition Corp. II Announces Pricing of $150,000,000 Initial Public Offering

Retrieved on: 
Wednesday, April 7, 2021

The Company is sponsored by EcoR1 Panacea Holdings II, LLC, an affiliate of EcoR1 Capital, LLC.

Key Points: 
  • The Company is sponsored by EcoR1 Panacea Holdings II, LLC, an affiliate of EcoR1 Capital, LLC.
  • Cowen is serving as the sole book-running manager for the offering.
  • The Company has granted the underwriters a 45-day option to purchase up to an additional 2,250,000 Class A ordinary shares at the initial public offering price to cover over-allotments, if any.
  • This press release contains statements that constitute forward-looking statements, including with respect to the proposed initial public offering and the anticipated use of the net proceeds.

Cowen Board of Directors Approves Increase in Share Repurchase Program to $25 million

Retrieved on: 
Thursday, March 18, 2021

NEW YORK, March 18, 2021 (GLOBE NEWSWIRE) -- Cowen Inc. (NASDAQ:COWN) (Cowen or the Company) today announced that its Board of Directors has approved an increase in the Companys existing share repurchase program (the Share Repurchase Program).

Key Points: 
  • NEW YORK, March 18, 2021 (GLOBE NEWSWIRE) -- Cowen Inc. (NASDAQ:COWN) (Cowen or the Company) today announced that its Board of Directors has approved an increase in the Companys existing share repurchase program (the Share Repurchase Program).
  • With this increase, the total amount now available for repurchase under the current plan is $25 million.
  • Cowen focuses on delivering value-added capabilities to our clients in order to help them outperform.
  • Founded in 1918, the Company is headquartered inNew Yorkand has offices worldwide.

Maravai LifeSciences Announces March 2021 Investor Conference Schedule

Retrieved on: 
Monday, March 1, 2021

OnMarch 3, 2021, Carl Hull, Chief Executive Officer, is scheduled to present at the Cowen Health Care Conference at10:20 a.m. PT.

Key Points: 
  • OnMarch 3, 2021, Carl Hull, Chief Executive Officer, is scheduled to present at the Cowen Health Care Conference at10:20 a.m. PT.
  • OnMarch 23, 2021, Hull will participate in a fireside chat at the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum at8:30 a.m. PT.
  • A live webcast of the presentations will be available to all interested parties on the Maravai Lifesciences investor relations website at http://investors.maravai.com .
  • Contact Information: Media Contact: Sara Michelmore MacDougall +1 781-235-3060 [email protected] Investor Contact: Deb Hart Maravai LifeSciences + 1 858-988-5917 [email protected]

Cowen Sustainable Investments Reaches Over $1.1 Billion in Platform Assets

Retrieved on: 
Wednesday, February 24, 2021

NEW YORK, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Cowen Sustainable Investments (CSI), a private sustainability investment strategy within the investment management division of Cowen Inc. (NASDAQ: COWN ), today announced it has successfully raised $919 million for its inaugural fund, bringing CSI platform assets to over $1.1 billion.

Key Points: 
  • NEW YORK, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Cowen Sustainable Investments (CSI), a private sustainability investment strategy within the investment management division of Cowen Inc. (NASDAQ: COWN ), today announced it has successfully raised $919 million for its inaugural fund, bringing CSI platform assets to over $1.1 billion.
  • The CSI platform leverages its partnership with investors to provide scaled, multi-hundred million dollar capital solutions per investment.
  • Led by Ewa Kozicz and Vusal Najafov, CSIs investment themes include clean transportation, sustainable food production, industrial efficiency as well as renewables and storage.
  • The CSI strategy is managed by Cowen Sustainable Advisors LLC, a division of Cowen Inc. ("Cowen").

Cerevel Therapeutics to Present at the Cowen 41st Annual Health Care Conference

Retrieved on: 
Tuesday, February 23, 2021

CAMBRIDGE, Mass., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain totreatneurosciencediseases, today announced that the company will participate in the upcoming Cowen 41st Annual Health Care Conference.

Key Points: 
  • CAMBRIDGE, Mass., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain totreatneurosciencediseases, today announced that the company will participate in the upcoming Cowen 41st Annual Health Care Conference.
  • The live webcast of the presentation can be accessed on the investor relations section of the Cerevel Therapeutics website here .
  • Cerevel Therapeutics is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases.
  • Forward-looking statements in this press release include, but are not limited to, statements about our participation in the upcoming Cowen 41st Annual Health Care Conference and the potential attributes and benefits of our product candidates.